Our Funds
All our funds, whether small-cap or mid-cap, are at least top decile performers for their corresponding vintages, with the 2014 MED I Fund ranking as #1 at a global level. Since inception in 2014, ARCHIMED has raised five main funds and their corresponding co-investment vehicles, all of them focused on growth buyout transactions and operating at the most demanding impact and sustainability standards for their corresponding vintages.
MED PLATFORM II
Vintage Year
2022
Total commitments
€3 500 000 000
Strategy
Growth Buyout / Mid-cap
Article
9
MED PLATFORM I
Vintage Year
2019
Total commitments
€1 000 000 000
Strategy
Growth Buyout / Mid-cap
Article
8
MED III
Vintage Year
2021
Total commitments
€650 000 000
Strategy
Growth Buyout / Lower Mid-cap
Article
8+
MED II
Vintage Year
2018
Total commitments
€315 000 000
Strategy
Growth Buyout / Small-cap
Article
8
MED I
Vintage Year
2014
Total commitments
€146 000 000
Strategy
Growth Buyout / Small-cap
Article
8
“All our funds are labelled Article 8 or 9 (maximum rating for their corresponding vintage), which reflects our engagement and investment strategy over the years to be fully oriented on impact.”
Vincent Guillaumot
Managing Partner
Art. 8
Funds
that promote environmental or social characteristics
Art. 9
Funds
that have sustainable investment as their objective
MED Access
Vintage Year
2024
Total commitments
Evergreen
Strategy
Full ARCHIMED Platform
Article
8+ or 9
MED Rise
Vintage Year
2024
Total commitments
€400 000 000
Strategy
Growth Buyout / Small-cap
Article
8+
MED Bio
Vintage Year
2024
Total commitments
€155 000 000
Strategy
Growth Buyout / Small-cap
Article
8
PolyMED
Vintage Year
2020
Total commitments
€177 147 000
Strategy
Growth Buyout / Small-cap
Article
8